Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
| Company | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency | Penalty Amount  |
|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2023 | DOJ_ANTITRUST | $275,000,000 |
| Dey Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Roxane Laboratories Inc. | Hikma Pharmaceuticals | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | fraud | 2005 | USAO | $300,000,000 |
| Pfizer, Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $371,351,180 |
| Indivior Inc. | Indivior PLC | pharmaceuticals | price-fixing or anti-competitive practices | 2024 | private lawsuit-federal | $385,000,000 |
| Novartis Pharmaceuticals | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Mylan Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2017 | DOJ_CIVIL | $465,000,000 |
| Mylan Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $465,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
| Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | drug or medical equipment safety violation | 2002 | DOJ_CIVIL | $500,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2016 | DOJ_CIVIL | $784,600,000 |
| Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Merck & Co., Inc. | Merck | pharmaceuticals | tax violations | 2007 | IRS | $2,300,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | product safety violation | 2021 | private lawsuit-federal | $2,500,000,000 |
| GlaxoSmithKline Holdings (Americas) | GlaxoSmithKline | pharmaceuticals | tax violations | 2006 | IRS | $3,400,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | product safety violation | 2023 | private lawsuit-federal | $8,900,000,000 |
